for Journals by Title or ISSN
for Articles by Keywords
help

Publisher: Oxford University Press   (Total: 409 journals)

 A  B  C  D  E  F  G  H  I  J  K  L  M  N  O  P  Q  R  S  T  U  V  W  X  Y  Z  

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Showing 1 - 200 of 409 Journals sorted alphabetically
ACS Symposium Series     Full-text available via subscription   (Followers: 1, SJR: 0.189, CiteScore: 0)
Acta Biochimica et Biophysica Sinica     Hybrid Journal   (Followers: 5, SJR: 0.79, CiteScore: 2)
Adaptation     Hybrid Journal   (Followers: 9, SJR: 0.143, CiteScore: 0)
Advances in Nutrition     Hybrid Journal   (Followers: 57, SJR: 2.196, CiteScore: 5)
Aesthetic Surgery J.     Hybrid Journal   (Followers: 6, SJR: 1.434, CiteScore: 1)
Aesthetic Surgery J. Open Forum     Open Access  
African Affairs     Hybrid Journal   (Followers: 69, SJR: 1.869, CiteScore: 2)
Age and Ageing     Hybrid Journal   (Followers: 91, SJR: 1.989, CiteScore: 4)
Alcohol and Alcoholism     Hybrid Journal   (Followers: 19, SJR: 1.376, CiteScore: 3)
American Entomologist     Hybrid Journal   (Followers: 8)
American Historical Review     Hybrid Journal   (Followers: 204, SJR: 0.467, CiteScore: 1)
American J. of Agricultural Economics     Hybrid Journal   (Followers: 47, SJR: 2.113, CiteScore: 3)
American J. of Clinical Nutrition     Hybrid Journal   (Followers: 209, SJR: 3.438, CiteScore: 6)
American J. of Epidemiology     Hybrid Journal   (Followers: 209, SJR: 2.713, CiteScore: 3)
American J. of Health-System Pharmacy     Full-text available via subscription   (Followers: 60, SJR: 0.595, CiteScore: 1)
American J. of Hypertension     Hybrid Journal   (Followers: 27, SJR: 1.322, CiteScore: 3)
American J. of Jurisprudence     Hybrid Journal   (Followers: 19, SJR: 0.281, CiteScore: 1)
American J. of Legal History     Full-text available via subscription   (Followers: 10, SJR: 0.116, CiteScore: 0)
American Law and Economics Review     Hybrid Journal   (Followers: 29, SJR: 1.053, CiteScore: 1)
American Literary History     Hybrid Journal   (Followers: 17, SJR: 0.391, CiteScore: 0)
Analysis     Hybrid Journal   (Followers: 24, SJR: 1.038, CiteScore: 1)
Animal Frontiers     Hybrid Journal   (Followers: 1)
Annals of Behavioral Medicine     Hybrid Journal   (Followers: 15, SJR: 1.423, CiteScore: 3)
Annals of Botany     Hybrid Journal   (Followers: 37, SJR: 1.721, CiteScore: 4)
Annals of Oncology     Hybrid Journal   (Followers: 56, SJR: 5.599, CiteScore: 9)
Annals of the Entomological Society of America     Full-text available via subscription   (Followers: 11, SJR: 0.722, CiteScore: 1)
Annals of Work Exposures and Health     Hybrid Journal   (Followers: 36, SJR: 0.728, CiteScore: 2)
Antibody Therapeutics     Open Access  
AoB Plants     Open Access   (Followers: 4, SJR: 1.28, CiteScore: 3)
Applied Economic Perspectives and Policy     Hybrid Journal   (Followers: 16, SJR: 0.858, CiteScore: 2)
Applied Linguistics     Hybrid Journal   (Followers: 59, SJR: 2.987, CiteScore: 3)
Applied Mathematics Research eXpress     Hybrid Journal   (Followers: 1, SJR: 1.241, CiteScore: 1)
Arbitration Intl.     Full-text available via subscription   (Followers: 22)
Arbitration Law Reports and Review     Hybrid Journal   (Followers: 14)
Archives of Clinical Neuropsychology     Hybrid Journal   (Followers: 31, SJR: 0.731, CiteScore: 2)
Aristotelian Society Supplementary Volume     Hybrid Journal   (Followers: 2)
Arthropod Management Tests     Hybrid Journal   (Followers: 2)
Astronomy & Geophysics     Hybrid Journal   (Followers: 45, SJR: 0.146, CiteScore: 0)
Behavioral Ecology     Hybrid Journal   (Followers: 55, SJR: 1.871, CiteScore: 3)
Bioinformatics     Hybrid Journal   (Followers: 385, SJR: 6.14, CiteScore: 8)
Biology Methods and Protocols     Hybrid Journal  
Biology of Reproduction     Full-text available via subscription   (Followers: 10, SJR: 1.446, CiteScore: 3)
Biometrika     Hybrid Journal   (Followers: 20, SJR: 3.485, CiteScore: 2)
BioScience     Hybrid Journal   (Followers: 30, SJR: 2.754, CiteScore: 4)
Bioscience Horizons : The National Undergraduate Research J.     Open Access   (Followers: 3, SJR: 0.146, CiteScore: 0)
Biostatistics     Hybrid Journal   (Followers: 17, SJR: 1.553, CiteScore: 2)
BJA : British J. of Anaesthesia     Hybrid Journal   (Followers: 206, SJR: 2.115, CiteScore: 3)
BJA Education     Hybrid Journal   (Followers: 67)
Brain     Hybrid Journal   (Followers: 73, SJR: 5.858, CiteScore: 7)
Briefings in Bioinformatics     Hybrid Journal   (Followers: 53, SJR: 2.505, CiteScore: 5)
Briefings in Functional Genomics     Hybrid Journal   (Followers: 3, SJR: 2.15, CiteScore: 3)
British J. for the Philosophy of Science     Hybrid Journal   (Followers: 41, SJR: 2.161, CiteScore: 2)
British J. of Aesthetics     Hybrid Journal   (Followers: 24, SJR: 0.508, CiteScore: 1)
British J. of Criminology     Hybrid Journal   (Followers: 607, SJR: 1.828, CiteScore: 3)
British J. of Social Work     Hybrid Journal   (Followers: 88, SJR: 1.019, CiteScore: 2)
British Medical Bulletin     Hybrid Journal   (Followers: 6, SJR: 1.355, CiteScore: 3)
British Yearbook of Intl. Law     Hybrid Journal   (Followers: 35)
Bulletin of the London Mathematical Society     Hybrid Journal   (Followers: 3, SJR: 1.376, CiteScore: 1)
Cambridge J. of Economics     Hybrid Journal   (Followers: 71, SJR: 0.764, CiteScore: 2)
Cambridge J. of Regions, Economy and Society     Hybrid Journal   (Followers: 12, SJR: 2.438, CiteScore: 4)
Cambridge Quarterly     Hybrid Journal   (Followers: 10, SJR: 0.104, CiteScore: 0)
Capital Markets Law J.     Hybrid Journal   (Followers: 2, SJR: 0.222, CiteScore: 0)
Carcinogenesis     Hybrid Journal   (Followers: 2, SJR: 2.135, CiteScore: 5)
Cardiovascular Research     Hybrid Journal   (Followers: 15, SJR: 3.002, CiteScore: 5)
Cerebral Cortex     Hybrid Journal   (Followers: 54, SJR: 3.892, CiteScore: 6)
CESifo Economic Studies     Hybrid Journal   (Followers: 24, SJR: 0.483, CiteScore: 1)
Chemical Senses     Hybrid Journal   (Followers: 1, SJR: 1.42, CiteScore: 3)
Children and Schools     Hybrid Journal   (Followers: 7, SJR: 0.246, CiteScore: 0)
Chinese J. of Comparative Law     Hybrid Journal   (Followers: 5, SJR: 0.412, CiteScore: 0)
Chinese J. of Intl. Law     Hybrid Journal   (Followers: 24, SJR: 0.329, CiteScore: 0)
Chinese J. of Intl. Politics     Hybrid Journal   (Followers: 11, SJR: 1.392, CiteScore: 2)
Christian Bioethics: Non-Ecumenical Studies in Medical Morality     Hybrid Journal   (Followers: 10, SJR: 0.183, CiteScore: 0)
Classical Receptions J.     Hybrid Journal   (Followers: 29, SJR: 0.123, CiteScore: 0)
Clean Energy     Open Access   (Followers: 1)
Clinical Infectious Diseases     Hybrid Journal   (Followers: 75, SJR: 5.051, CiteScore: 5)
Communication Theory     Hybrid Journal   (Followers: 26, SJR: 2.424, CiteScore: 3)
Communication, Culture & Critique     Hybrid Journal   (Followers: 28, SJR: 0.222, CiteScore: 1)
Community Development J.     Hybrid Journal   (Followers: 28, SJR: 0.268, CiteScore: 1)
Computer J.     Hybrid Journal   (Followers: 9, SJR: 0.319, CiteScore: 1)
Conservation Physiology     Open Access   (Followers: 3, SJR: 1.818, CiteScore: 3)
Contemporary Women's Writing     Hybrid Journal   (Followers: 10, SJR: 0.121, CiteScore: 0)
Contributions to Political Economy     Hybrid Journal   (Followers: 6, SJR: 0.906, CiteScore: 1)
Critical Values     Full-text available via subscription  
Current Developments in Nutrition     Open Access   (Followers: 4)
Current Legal Problems     Hybrid Journal   (Followers: 29)
Current Zoology     Full-text available via subscription   (Followers: 4, SJR: 1.164, CiteScore: 2)
Database : The J. of Biological Databases and Curation     Open Access   (Followers: 9, SJR: 1.791, CiteScore: 3)
Digital Scholarship in the Humanities     Hybrid Journal   (Followers: 14, SJR: 0.259, CiteScore: 1)
Diplomatic History     Hybrid Journal   (Followers: 24, SJR: 0.45, CiteScore: 1)
DNA Research     Open Access   (Followers: 5, SJR: 2.866, CiteScore: 6)
Dynamics and Statistics of the Climate System     Open Access   (Followers: 4)
Early Music     Hybrid Journal   (Followers: 17, SJR: 0.139, CiteScore: 0)
Econometrics J.     Hybrid Journal   (Followers: 32, SJR: 2.926, CiteScore: 1)
Economic J.     Hybrid Journal   (Followers: 118, SJR: 5.161, CiteScore: 3)
Economic Policy     Hybrid Journal   (Followers: 49, SJR: 3.584, CiteScore: 3)
ELT J.     Hybrid Journal   (Followers: 25, SJR: 0.942, CiteScore: 1)
English Historical Review     Hybrid Journal   (Followers: 57, SJR: 0.612, CiteScore: 1)
English: J. of the English Association     Hybrid Journal   (Followers: 21, SJR: 0.1, CiteScore: 0)
Environmental Entomology     Full-text available via subscription   (Followers: 12, SJR: 0.818, CiteScore: 2)
Environmental Epigenetics     Open Access   (Followers: 2)
Environmental History     Hybrid Journal   (Followers: 26, SJR: 0.408, CiteScore: 1)
EP-Europace     Hybrid Journal   (Followers: 3, SJR: 2.748, CiteScore: 4)
Epidemiologic Reviews     Hybrid Journal   (Followers: 9, SJR: 4.505, CiteScore: 8)
ESHRE Monographs     Hybrid Journal  
Essays in Criticism     Hybrid Journal   (Followers: 22, SJR: 0.113, CiteScore: 0)
European Heart J.     Hybrid Journal   (Followers: 68, SJR: 9.315, CiteScore: 9)
European Heart J. - Cardiovascular Imaging     Hybrid Journal   (Followers: 10, SJR: 3.625, CiteScore: 3)
European Heart J. - Cardiovascular Pharmacotherapy     Full-text available via subscription   (Followers: 3)
European Heart J. - Quality of Care and Clinical Outcomes     Hybrid Journal  
European Heart J. : Case Reports     Open Access   (Followers: 1)
European Heart J. Supplements     Hybrid Journal   (Followers: 8, SJR: 0.223, CiteScore: 0)
European J. of Cardio-Thoracic Surgery     Hybrid Journal   (Followers: 9, SJR: 1.681, CiteScore: 2)
European J. of Intl. Law     Hybrid Journal   (Followers: 217, SJR: 0.694, CiteScore: 1)
European J. of Orthodontics     Hybrid Journal   (Followers: 5, SJR: 1.279, CiteScore: 2)
European J. of Public Health     Hybrid Journal   (Followers: 21, SJR: 1.36, CiteScore: 2)
European Review of Agricultural Economics     Hybrid Journal   (Followers: 10, SJR: 1.172, CiteScore: 2)
European Review of Economic History     Hybrid Journal   (Followers: 30, SJR: 0.702, CiteScore: 1)
European Sociological Review     Hybrid Journal   (Followers: 44, SJR: 2.728, CiteScore: 3)
Evolution, Medicine, and Public Health     Open Access   (Followers: 12)
Family Practice     Hybrid Journal   (Followers: 15, SJR: 1.018, CiteScore: 2)
Fems Microbiology Ecology     Hybrid Journal   (Followers: 19, SJR: 1.492, CiteScore: 4)
Fems Microbiology Letters     Hybrid Journal   (Followers: 29, SJR: 0.79, CiteScore: 2)
Fems Microbiology Reviews     Hybrid Journal   (Followers: 37, SJR: 7.063, CiteScore: 13)
Fems Yeast Research     Hybrid Journal   (Followers: 14, SJR: 1.308, CiteScore: 3)
Food Quality and Safety     Open Access   (Followers: 1)
Foreign Policy Analysis     Hybrid Journal   (Followers: 25, SJR: 1.425, CiteScore: 1)
Forest Science     Hybrid Journal   (Followers: 8, SJR: 0.89, CiteScore: 2)
Forestry: An Intl. J. of Forest Research     Hybrid Journal   (Followers: 16, SJR: 1.133, CiteScore: 3)
Forum for Modern Language Studies     Hybrid Journal   (Followers: 6, SJR: 0.104, CiteScore: 0)
French History     Hybrid Journal   (Followers: 35, SJR: 0.118, CiteScore: 0)
French Studies     Hybrid Journal   (Followers: 21, SJR: 0.148, CiteScore: 0)
French Studies Bulletin     Hybrid Journal   (Followers: 10, SJR: 0.152, CiteScore: 0)
Gastroenterology Report     Open Access   (Followers: 3)
Genome Biology and Evolution     Open Access   (Followers: 17, SJR: 2.578, CiteScore: 4)
Geophysical J. Intl.     Hybrid Journal   (Followers: 38, SJR: 1.506, CiteScore: 3)
German History     Hybrid Journal   (Followers: 24, SJR: 0.161, CiteScore: 0)
GigaScience     Open Access   (Followers: 6, SJR: 5.022, CiteScore: 7)
Global Summitry     Hybrid Journal   (Followers: 1)
Glycobiology     Hybrid Journal   (Followers: 12, SJR: 1.493, CiteScore: 3)
Health and Social Work     Hybrid Journal   (Followers: 60, SJR: 0.388, CiteScore: 1)
Health Education Research     Hybrid Journal   (Followers: 15, SJR: 0.854, CiteScore: 2)
Health Policy and Planning     Hybrid Journal   (Followers: 25, SJR: 1.512, CiteScore: 2)
Health Promotion Intl.     Hybrid Journal   (Followers: 23, SJR: 0.812, CiteScore: 2)
History Workshop J.     Hybrid Journal   (Followers: 33, SJR: 1.278, CiteScore: 1)
Holocaust and Genocide Studies     Hybrid Journal   (Followers: 29, SJR: 0.105, CiteScore: 0)
Human Communication Research     Hybrid Journal   (Followers: 15, SJR: 2.146, CiteScore: 3)
Human Molecular Genetics     Hybrid Journal   (Followers: 9, SJR: 3.555, CiteScore: 5)
Human Reproduction     Hybrid Journal   (Followers: 75, SJR: 2.643, CiteScore: 5)
Human Reproduction Open     Open Access   (Followers: 1)
Human Reproduction Update     Hybrid Journal   (Followers: 20, SJR: 5.317, CiteScore: 10)
Human Rights Law Review     Hybrid Journal   (Followers: 65, SJR: 0.756, CiteScore: 1)
ICES J. of Marine Science: J. du Conseil     Hybrid Journal   (Followers: 62, SJR: 1.591, CiteScore: 3)
ICSID Review : Foreign Investment Law J.     Hybrid Journal   (Followers: 12)
ILAR J.     Hybrid Journal   (Followers: 3, SJR: 1.732, CiteScore: 4)
IMA J. of Applied Mathematics     Hybrid Journal   (SJR: 0.679, CiteScore: 1)
IMA J. of Management Mathematics     Hybrid Journal   (SJR: 0.538, CiteScore: 1)
IMA J. of Mathematical Control and Information     Hybrid Journal   (Followers: 2, SJR: 0.496, CiteScore: 1)
IMA J. of Numerical Analysis - advance access     Hybrid Journal   (SJR: 1.987, CiteScore: 2)
Industrial and Corporate Change     Hybrid Journal   (Followers: 10, SJR: 1.792, CiteScore: 2)
Industrial Law J.     Hybrid Journal   (Followers: 44, SJR: 0.249, CiteScore: 1)
Inflammatory Bowel Diseases     Hybrid Journal   (Followers: 45, SJR: 2.511, CiteScore: 4)
Information and Inference     Free  
Innovation in Aging     Open Access   (Followers: 1)
Insect Systematics and Diversity     Hybrid Journal  
Integrative and Comparative Biology     Hybrid Journal   (Followers: 10, SJR: 1.319, CiteScore: 2)
Integrative Biology     Full-text available via subscription   (Followers: 5, SJR: 1.36, CiteScore: 3)
Integrative Organismal Biology     Open Access  
Interacting with Computers     Hybrid Journal   (Followers: 10, SJR: 0.292, CiteScore: 1)
Interactive CardioVascular and Thoracic Surgery     Hybrid Journal   (Followers: 7, SJR: 0.762, CiteScore: 1)
Intl. Affairs     Hybrid Journal   (Followers: 68, SJR: 1.505, CiteScore: 3)
Intl. Data Privacy Law     Hybrid Journal   (Followers: 26)
Intl. Health     Hybrid Journal   (Followers: 6, SJR: 0.851, CiteScore: 2)
Intl. Immunology     Hybrid Journal   (Followers: 3, SJR: 2.167, CiteScore: 4)
Intl. J. for Quality in Health Care     Hybrid Journal   (Followers: 37, SJR: 1.348, CiteScore: 2)
Intl. J. of Constitutional Law     Hybrid Journal   (Followers: 62, SJR: 0.601, CiteScore: 1)
Intl. J. of Epidemiology     Hybrid Journal   (Followers: 270, SJR: 3.969, CiteScore: 5)
Intl. J. of Law and Information Technology     Hybrid Journal   (Followers: 5, SJR: 0.202, CiteScore: 1)
Intl. J. of Law, Policy and the Family     Hybrid Journal   (Followers: 25, SJR: 0.223, CiteScore: 1)
Intl. J. of Lexicography     Hybrid Journal   (Followers: 9, SJR: 0.285, CiteScore: 1)
Intl. J. of Low-Carbon Technologies     Open Access   (Followers: 1, SJR: 0.403, CiteScore: 1)
Intl. J. of Neuropsychopharmacology     Open Access   (Followers: 3, SJR: 1.808, CiteScore: 4)
Intl. J. of Public Opinion Research     Hybrid Journal   (Followers: 11, SJR: 1.545, CiteScore: 1)
Intl. J. of Refugee Law     Hybrid Journal   (Followers: 40, SJR: 0.389, CiteScore: 1)
Intl. J. of Transitional Justice     Hybrid Journal   (Followers: 13, SJR: 0.724, CiteScore: 2)
Intl. Mathematics Research Notices     Hybrid Journal   (Followers: 1, SJR: 2.168, CiteScore: 1)
Intl. Political Sociology     Hybrid Journal   (Followers: 40, SJR: 1.465, CiteScore: 3)
Intl. Relations of the Asia-Pacific     Hybrid Journal   (Followers: 24, SJR: 0.401, CiteScore: 1)
Intl. Studies Perspectives     Hybrid Journal   (Followers: 9, SJR: 0.983, CiteScore: 1)
Intl. Studies Quarterly     Hybrid Journal   (Followers: 53, SJR: 2.581, CiteScore: 2)
Intl. Studies Review     Hybrid Journal   (Followers: 24, SJR: 1.201, CiteScore: 1)
ISLE: Interdisciplinary Studies in Literature and Environment     Hybrid Journal   (Followers: 2, SJR: 0.15, CiteScore: 0)
ITNOW     Hybrid Journal   (Followers: 1, SJR: 0.103, CiteScore: 0)
J. of African Economies     Hybrid Journal   (Followers: 18, SJR: 0.533, CiteScore: 1)
J. of American History     Hybrid Journal   (Followers: 50, SJR: 0.297, CiteScore: 1)
J. of Analytical Toxicology     Hybrid Journal   (Followers: 14, SJR: 1.065, CiteScore: 2)
J. of Antimicrobial Chemotherapy     Hybrid Journal   (Followers: 16, SJR: 2.419, CiteScore: 4)
J. of Antitrust Enforcement     Hybrid Journal   (Followers: 1)
J. of Applied Poultry Research     Hybrid Journal   (Followers: 5, SJR: 0.585, CiteScore: 1)
J. of Biochemistry     Hybrid Journal   (Followers: 43, SJR: 1.226, CiteScore: 2)
J. of Breast Imaging     Full-text available via subscription   (Followers: 2)

        1 2 3 | Last   [Sort by number of followers]   [Restore default list]

Similar Journals
Journal Cover
Clinical Infectious Diseases
Journal Prestige (SJR): 5.051
Citation Impact (citeScore): 5
Number of Followers: 75  
 
  Hybrid Journal Hybrid journal (It can contain Open Access articles)
ISSN (Print) 1058-4838 - ISSN (Online) 1537-6591
Published by Oxford University Press Homepage  [409 journals]
  • In the Literature
    • PubDate: Wed, 27 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz922
      Issue No: Vol. 69, No. 12 (2019)
       
  • News
    • PubDate: Wed, 27 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz884
      Issue No: Vol. 69, No. 12 (2019)
       
  • 2019 CID Reviewer Recognition List
    • Abstract: The editors of Clinical Infectious Diseases thank the following reviewers for their time and efforts. The quality of the journal depends in large part on their expertise.
      PubDate: Wed, 27 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1022
      Issue No: Vol. 69, No. 12 (2019)
       
  • Charting the Path Forward: Development, Goals and Initiatives of the 2019
           Infectious Diseases of America Strategic Plan
    • Authors: Sears C; File T, Alexander B, et al.
      Abstract: AbstractIn October 2018, the Infectious Diseases Society of America (IDSA) Board of Directors (BOD) decided to develop a 2019 IDSA Strategic Plan. The IDSA BOD has invested in strategic planning at regular intervals as part of an ongoing process to review and to renew the vision and direction of IDSA. Herein, the 2018–2019 strategic planning process and outcomes are described. The 2019 IDSA Strategic Plan presents 4 key initiatives: (1) optimize the development, dissemination, and adoption of timely and relevant ID guidance and guidelines that improve the outcomes of clinical care; (2) quantify, communicate, and advocate for the value of ID physicians to increase professional fulfillment and compensation; (3) facilitate the growth and development of the ID workforce to meet emerging scientific, clinical, and leadership needs; and (4) develop and position a new tool to serve as the leading US benchmark to measure and drive national progress on antimicrobial resistance. The BOD looks forward to developing, implementing, assessing, and advancing the 2019 IDSA Strategic Plan working with member volunteers, Society partners, and IDSA staff.
      PubDate: Thu, 17 Oct 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1040
      Issue No: Vol. 69, No. 12 (2019)
       
  • Fosfomycin for Injection (ZTI-01) Versus Piperacillin-tazobactam for the
           Treatment of Complicated Urinary Tract Infection Including Acute
           Pyelonephritis: ZEUS, A Phase 2/3 Randomized Trial
    • Authors: Kaye K; Rice L, Dane A, et al.
      Pages: 2045 - 2056
      Abstract: AbstractBackgroundZTI-01 (fosfomycin for injection) is an epoxide antibiotic with a differentiated mechanism of action (MOA) inhibiting an early step in bacterial cell wall synthesis. ZTI-01 has broad in vitro spectrum of activity, including multidrug-resistant Gram-negative pathogens, and is being developed for treatment of complicated urinary tract infection (cUTI) and acute pyelonephritis (AP) in the United States.MethodsHospitalized adults with suspected or microbiologically confirmed cUTI/AP were randomized 1:1 to 6 g ZTI-01 q8h or 4.5 g intravenous (IV) piperacillin-tazobactam (PIP-TAZ) q8h for a fixed 7-day course (no oral switch); patients with concomitant bacteremia could receive up to 14 days.ResultsOf 465 randomized patients, 233 and 231 were treated with ZTI-01 and PIP-TAZ, respectively. In the microbiologic modified intent-to-treat (m-MITT) population, ZTI-01 met the primary objective of noninferiority compared with PIP-TAZ with overall success rates of 64.7% (119/184 patients) vs 54.5% (97/178 patients), respectively; treatment difference was 10.2% (95% confidence interval [CI]: −0.4, 20.8). Clinical cure rates at test of cure (TOC, day 19–21) were high and similar between treatments (90.8% [167/184] vs 91.6% [163/178], respectively). In post hoc analysis using unique pathogens typed by pulsed-field gel electrophoresis, overall success rates at TOC in m-MITT were 69.0% (127/184) for ZTI-01 versus 57.3% (102/178) for PIP-TAZ (difference 11.7% 95% CI: 1.3, 22.1). ZTI-01 was well tolerated. Most treatment-emergent adverse events, including hypokalemia and elevated serum aminotransferases, were mild and transient.ConclusionsZTI-01 was effective for treatment of cUTI including AP and offers a new IV therapeutic option with a differentiated MOA for patients with serious Gram-negative infections.Clinical Trial RegistrationNCT02753946
      PubDate: Wed, 06 Mar 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz181
      Issue No: Vol. 69, No. 12 (2019)
       
  • By ZEUS! Can We Use Intravenous Fosfomycin for Complicated Urinary Tract
           Infections'
    • Authors: Harris P.
      Pages: 2057 - 2058
      Abstract: (See the Major article by Kaye et al on pages 2045–56.)
      PubDate: Mon, 06 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz185
      Issue No: Vol. 69, No. 12 (2019)
       
  • Impact of Rotavirus Vaccine Introduction in Children Less Than 2 Years of
           
    • Authors: Schwartz L; Zaman K, Yunus M, et al.
      Pages: 2059 - 2070
      Abstract: AbstractBackgroundFollowing the conclusion of a human rotavirus vaccine (HRV) cluster-randomized, controlled trial (CRT) in Matlab, Bangladesh, HRV was included in Matlab’s routine immunization program. We describe the population-level impact of programmatic rotavirus vaccination in Bangladesh in children <2 years of age.MethodsInterrupted time series were used to estimate the impact of HRV introduction. We used diarrheal surveillance collected between 2000 and 2014 within the 2 service delivery areas (International Centre for Diarrhoeal Disease Research, Bangladesh [icddr,b] service area [ISA] and government service area [GSA]) of the Matlab Health and Demographic Surveillance System, administered by icddr,b. Age group–specific incidence rates were calculated for both rotavirus-positive (RV+) and rotavirus-negative (RV–) diarrhea diagnoses of any severity presenting to the hospital. We used 2 models to assess the impact within each service area: Model 1 used the pre-vaccine time period in all villages (HRV– and control-only) and Model 2 combined the pre-vaccine time period and the CRT time period, using outcomes from control-only villages.ResultsBoth models demonstrated a downward trend in RV+ diarrheal incidences in the ISA villages during 3.5 years of routine HRV use, though only Model 2 was statistically significant. Significant impacts of HRV on RV+ diarrhea incidences in GSA villages were not observed in either model. Differences in population-level impacts between the 2 delivery areas may be due to the varied rotavirus vaccine coverage and presentation rates to the hospital.ConclusionsThis study provides initial evidence of the population-level impact of rotavirus vaccines in children <2 years of age in Matlab, Bangladesh. Further studies are needed of the rotavirus vaccine impact after the nationwide introduction in Bangladesh.
      PubDate: Tue, 12 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz133
      Issue No: Vol. 69, No. 12 (2019)
       
  • Rotavirus Vaccines Set to Make Inroads in Asia
    • Authors: Steele A; Parashar U.
      Pages: 2071 - 2073
      Abstract: (See the Major article by Schwartz et al on pages 2059–70.)
      PubDate: Wed, 13 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz137
      Issue No: Vol. 69, No. 12 (2019)
       
  • The Impact of Improved Water, Sanitation, and Hygiene on Oral Rotavirus
           Vaccine Immunogenicity in Zimbabwean Infants: Substudy of a
           Cluster-randomized Trial
    • Authors: Church J; Rukobo S, Govha M, et al.
      Pages: 2074 - 2081
      Abstract: AbstractBackgroundOral vaccines have lower efficacy in developing compared to developed countries. Poor water, sanitation, and hygiene (WASH) may contribute to reduced oral vaccine immunogenicity.MethodsWe conducted a cluster-randomized 2 × 2 factorial trial in rural Zimbabwe. Pregnant women and their infants were eligible if they lived in clusters randomized to (1) standard of care (52 clusters); (2) improved infant feeding (53 clusters); (3) WASH: ventilated improved pit latrine, 2 hand-washing stations, liquid soap, chlorine, infant play space, and hygiene counseling (53 clusters); or (4) feeding plus WASH (53 clusters). This substudy compared oral rotavirus vaccine (RVV) seroconversion (primary outcome), and seropositivity and geometric mean titer (GMT) (secondary outcomes), in WASH vs non-WASH infants by intention-to-treat analysis.ResultsWe included 801 infants with documented RVV receipt and postvaccine titer measurements (329 from 84 WASH clusters; 472 from 102 non-WASH clusters); 328 infants with prevaccination titers were included in the primary outcome. Thirty-three of 109 (30.3%) infants in the WASH group seroconverted following rotavirus vaccination, compared to 43 of 219 (19.6%) in the non-WASH group (absolute difference, 10.6% [95% confidence interval {CI}, .54%–20.7%]; P = .031). In the WASH vs non-WASH groups, 90 of 329 (27.4%) vs 107 of 472 (22.7%) were seropositive postvaccination (absolute difference, 4.7% [95% CI, –1.4% to 10.8%]; P = .130), and antirotavirus GMT was 18.4 (95% CI, 15.6–21.7) U/mL vs 14.9 (95% CI, 13.2–16.8) U/mL (P = .072).ConclusionsImprovements in household WASH led to modest but significant increases in seroconversion to RVV in rural Zimbabwean infants.Clinical Trials RegistrationNCT01824940.
      PubDate: Fri, 29 Mar 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz140
      Issue No: Vol. 69, No. 12 (2019)
       
  • A Dose-finding Study of a Wild-type Influenza A(H3N2) Virus in a Healthy
           Volunteer Human Challenge Model
    • Authors: Han A; Czajkowski L, Donaldson A, et al.
      Pages: 2082 - 2090
      Abstract: AbstractBackgroundThe development of vaccines and therapeutics has relied on healthy volunteer influenza challenge studies. A validated human infection model with wild-type A(H1N1)pdm09 was reported previously. Our objective was to characterize a wild-type influenza A/Bethesda/MM1/H3N2 challenge virus in healthy volunteers.MethodsParticipants received a single dose of a cell-based, reverse-genetics, Good Manufacturing Practices–produced wild-type influenza A(H3N2)2011 virus intranasally and were isolated at the National Institutes of Health Clinical Center for ≥9 days. Dose escalation was performed from 104 to 107 TCID50 (50% tissue culture infectious dose). Viral shedding and clinical disease were evaluated daily.ResultsOf 37 participants challenged, 16 (43%) had viral shedding and 27 (73%) developed symptoms, with 12 (32%) participants experiencing mild to moderate influenza disease (MMID), defined as shedding and symptoms. Only participants receiving 106 and 107 TCID50 experienced MMID at 44% and 40%, respectively. Symptom severity peaked on day 3, whereas most viral shedding occurred 1–2 days after challenge. Only 10 (29%) participants had a ≥4-fold rise in hemagglutination inhibition antibody titer after challenge.ConclusionsThe A/Bethesda/MM1/H3N2 challenge virus safely induced MMID in healthy volunteers, but caused less MMID than the A(H1N1)pdm09 challenge virus even at the highest dose. There was less detection of shedding though the incidence of symptoms was similar to A(H1N1)pdm09. Fewer serum anti-hemagglutinin (HA) antibody responses with less MMID indicate that preexisting immunity factors other than anti-HA antibody may limit shedding in healthy volunteers. This A/Bethesda/MM1/H3N2 challenge virus can be utilized in future studies to further explore pathogenesis and immunity and to evaluate vaccine candidates.Clinical Trials RegistrationNCT02594189
      PubDate: Sat, 16 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz141
      Issue No: Vol. 69, No. 12 (2019)
       
  • Differences by Sex in Cardiovascular Comorbid Conditions Among Older
           Adults (Aged 50–64 or ≥65 Years) Receiving Care for Human
           Immunodeficiency Virus
    • Authors: Frazier E; Sutton M, Tie Y, et al.
      Pages: 2091 - 2100
      Abstract: BackgroundDifferences by sex in cardiovascular comorbid conditions among human immunodeficiency virus (HIV)–infected persons aged 50–64 years have been understudied; even fewer data are available for persons aged ≥65 years.MethodsWe used matched interview and medical record abstraction data from the 2009–2012 data cycles of the Medical Monitoring Project, a nationally representative sample of HIV-infected adults in care. We included men and women aged 50–64 and ≥65 years at time of interview. We calculated weighted prevalence estimates and used logistic regression to compute adjusted prevalence differences and 95% confidence intervals (CIs) assessing sex differences in various characteristics and cardiovascular comorbid conditions. Comorbid conditions included overweight/obesity (body mass index ≥25), abnormal total cholesterol level (defined as ≥200 mg/dL), diagnosed diabetes mellitus, or diagnosed hypertension.ResultsOf 7436 participants, 89.5% were aged 50–64 years and 10.4% aged ≥65 years, 75.1% were men, 40.4% (95% CI, 33.5%–47.2%) were non-Hispanic black, 72.0% (70.4%–73.6%) had HIV infection diagnosed ≥10 years earlier. After adjustment for sociodemographic and behavioral factors, women aged 50–64 years were more likely than men to be obese (adjusted prevalence difference, 8.4; 95% CI, 4.4–12.3), have hypertension (3.9; .1–7.6), or have high total cholesterol levels (9.9; 6.2–13.6). Women aged ≥65 years had higher prevalences of diabetes mellitus and high total cholesterol levels than men.ConclusionsCardiovascular comorbid conditions were prevalent among older HIV-infected persons in care; disparities existed by sex. Closer monitoring and risk-reduction strategies for cardiovascular comorbid conditions are warranted for older HIV-infected persons, especially older women.
      PubDate: Fri, 03 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz126
      Issue No: Vol. 69, No. 12 (2019)
       
  • Estimated Impact of World Health Organization Latent Tuberculosis
           Screening Guidelines in a Region With a Low Tuberculosis Incidence:
           Retrospective Cohort Study
    • Authors: Ronald L; Campbell J, Rose C, et al.
      Pages: 2101 - 2108
      Abstract: AbstractBackgroundLatent tuberculosis infection (LTBI) screening and treatment is a key component of the World Health Organization (WHO) EndTB Strategy, but the impact of LTBI screening and treatment at a population level is unclear. We aimed to estimate the impact of LTBI screening and treatment in a population of migrants to British Columbia (BC), Canada.MethodsThis retrospective cohort included all individuals (N = 1 080 908) who immigrated to Canada as permanent residents between 1985 and 2012 and were residents in BC at any time up to 2013. Multiple administrative databases were linked to identify people with risk factors who met the WHO strong recommendations for screening: people with tuberculosis (TB) contact, with human immunodeficiency virus, on dialysis, with tumor necrosis factor-alpha inhibitors, who had an organ/haematological transplant, or with silicosis. Additional TB risk factors included immunosuppressive medications, cancer, diabetes, and migration from a country with a high TB burden. We defined active TB as preventable if diagnosed ≥6 months after a risk factor diagnosis. We estimated the number of preventable TB cases, given optimal LTBI screening and treatment, based on these risk factors.ResultsThere were 16 085 people (1.5%) identified with WHO strong risk factors. Of the 2814 people with active TB, 118 (4.2%) were considered preventable through screening with WHO risk factors. Less than half (49.4%) were considered preventable with expanded screening to include people migrating from countries with high TB burdens, people who had been prescribed immunosuppressive medications, or people with diabetes or cancer.ConclusionsThe application of WHO LTBI strong recommendations for screening would have minimally impacted the TB incidence in this population. Further high-risk groups must be identified to develop an effective LTBI screening and treatment strategy for low-incidence regions.
      PubDate: Mon, 11 Mar 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz188
      Issue No: Vol. 69, No. 12 (2019)
       
  • Preventing Tuberculosis Disease: Making a Case for Enhanced Tuberculosis
           Screening in People Immigrating to Low-incidence Countries
    • Authors: Katrak S; Barry P.
      Pages: 2109 - 2111
      Abstract: tuberculosislatent infectionepidemiology
      PubDate: Mon, 11 Mar 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz192
      Issue No: Vol. 69, No. 12 (2019)
       
  • Methicillin-susceptible and Methicillin-resistant Staphylococcus aureus
           Bacteremia: Nationwide Estimates of 30-Day Readmission, In-hospital
           Mortality, Length of Stay, and Cost in the United States
    • Authors: Inagaki K; Lucar J, Blackshear C, et al.
      Pages: 2112 - 2118
      Abstract: AbstractBackgroundInformation on outcomes of methicillin-susceptible and -resistant Staphylococcus aureus (MSSA and MRSA, respectively) bacteremia, particularly readmission, is scarce and requires further research to inform optimal patient care.MethodsWe performed a retrospective analysis using the 2014 Nationwide Readmissions Database, capturing 49.3% of US hospitalizations. We identified MSSA and MRSA bacteremia using International Classification of Diseases, Ninth Revision, Clinical Modification among patients aged ≥18 years. Thirty-day readmission, mortality, length of stay, and costs were assessed using Cox proportional hazards regression, logistic regression, Poisson regression, and generalized linear model with gamma distribution and log link, respectively.ResultsOf 92 089 (standard error [SE], 1905) patients with S. aureus bacteremia, 48.5% (SE, 0.4%) had MRSA bacteremia. Thirty-day readmission rate was 22% (SE, 0.3) overall with no difference between MRSA and MSSA, but MRSA bacteremia had more readmission for bacteremia recurrence (hazard ratio, 1.17 [95% confidence interval {CI}, 1.02–1.34]), higher in-hospital mortality (odds ratio, 1.15 [95% CI, 1.07–1.23]), and longer hospitalization (incidence rate ratio, 1.09 [95% CI, 1.06–1.11]). Readmission with bacteremia recurrence was particularly more common among patients with endocarditis, immunocompromising comorbidities, and drug abuse. The cost of readmission was $12 425 (SE, $174) per case overall, and $19 186 (SE, $623) in those with bacteremia recurrence.ConclusionsThirty-day readmission after S. aureus bacteremia is common and costly. MRSA bacteremia is associated with readmission for bacteremia recurrence, increased mortality, and longer hospitalization. Efforts should continue to optimize patient care, particularly for those with risk factors, to decrease readmission and associated morbidity and mortality in patients with S. aureus bacteremia.
      PubDate: Mon, 11 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz123
      Issue No: Vol. 69, No. 12 (2019)
       
  • Prospective Clinical and Molecular Evaluation of Potential Plasmodium
           ovale curtisi and wallikeri Relapses in a High-transmission Setting
    • Authors: Groger M; Veletzky L, Lalremruata A, et al.
      Pages: 2119 - 2126
      Abstract: AbstractBackgroundPlasmodium ovale curtisi and wallikeri are perceived as relapsing malarial parasites. Contrary to Plasmodium vivax, direct evidence for this hypothesis is scarce. The aim of this prospective study was to characterize the reappearance patterns of ovale parasites.MethodsP. ovale spp. infected patients were treated with artemether-lumefantrine and followed biweekly for up to 1 year for the detection of reappearing parasitemia. Molecular analysis of reappearing isolates was performed to identify homologous isolates by genotyping and to define cases of relapse following predefined criteria.ResultsAt inclusion, 26 participants were positive for P. ovale curtisi and/or P. ovale wallikeri. The median duration of follow-up was 35 weeks. Reappearance of the same P. ovale species was observed in 46% of participants; 61% of P. ovale curtisi and 19% of P. ovale wallikeri infection-free intervals were estimated to end with reappearance by week 32. Based on the predefined criteria, 23% of participants were identified with 1 or 2 relapses, all induced by P. ovale curtisi.ConclusionThese findings are in line with the currently accepted relapse theory inasmuch as the reappearance of P. ovale curtisi strains following initial blood clearance was conclusively demonstrated. Interestingly, no relapse of P. ovale wallikeri was observed.
      PubDate: Fri, 19 Apr 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz131
      Issue No: Vol. 69, No. 12 (2019)
       
  • Patterns of Hepatitis C Virus Transmission in Human Immunodeficiency Virus
           (HIV)–infected and HIV-negative Men Who Have Sex With Men
    • Authors: Ramière C; Charre C, Miailhes P, et al.
      Pages: 2127 - 2135
      Abstract: AbstractBackgroundSexually transmitted acute hepatitis C virus (HCV) infections (AHIs) have been mainly described in human immunodeficiency virus (HIV)–infected men who have sex with men (MSM). Cases in HIV-negative MSM are scarce. We describe the epidemic of AHI in HIV-infected and HIV-negative MSM in Lyon, France.MethodsAll cases of AHI diagnosed in MSM in Lyon University Hospital from 2014 to 2017 were included. AHI incidence was determined in HIV-infected and in preexposure prophylaxis (PrEP)–using MSM. Transmission clusters were identified by construction of phylogenetic trees based on HCV NS5B (genotype 1a/4d) or NS5A (genotype 3a) Sanger sequencing.ResultsFrom 2014 to 2017, 108 AHIs (80 first infections, 28 reinfections) were reported in 96 MSM (HIV-infected, 72; HIV-negative, 24). AHI incidence rose from 1.1/100 person-years (95 confidence interval [CI], 0.7–1.7) in 2014 to 2.4/100 person-years (95 CI, 1.1–2.6) in 2017 in HIV-infected MSM (P = .05) and from 0.3/100 person-years (95 CI, 0.06–1.0) in 2016 to 3.4/100 person-years (95 CI, 2.0–5.5) in 2017 in PrEP users (P < .001). Eleven clusters were identified. All clusters included HIV-infected MSM; 6 also included HIV-negative MSM. All clusters started with ≥1 HIV-infected MSM. Risk factor distribution varied among clusters.ConclusionsAHI incidence increased in both HIV-infected and HIV-negative MSM. Cluster analysis suggests initial transmission from HIV-infected to HIV-negative MSM through chemsex and traumatic sexual practices, leading to mixed patterns of transmission regardless of HIV status and no overlap with the general population.
      PubDate: Wed, 27 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz160
      Issue No: Vol. 69, No. 12 (2019)
       
  • Seroprotection at Different Levels of the Healthcare System After Routine
           Vaccination With Diphtheria-Tetanus-Pertussis whole cell–Hepatitis
           B–Haemophilus influenzae Type B in Lao People’s Democratic Republic
    • Authors: Hefele L; Syphan S, Xayavong D, et al.
      Pages: 2136 - 2144
      Abstract: AbstractBackgroundThe Lao People’s Democratic Republic continues to sustain a considerable burden of vaccine-preventable diseases because of incomplete vaccine coverage and weak vaccine responses. We have assessed seroconversion after routine vaccination with the pentavalent vaccine to capture weaknesses of vaccine management at the different levels of the healthcare system.MethodsA total of 1151 children (aged 8–28 months) with 3 documented doses of the pentavalent vaccine delivered at central hospitals in Vientiane and the provincial hospital, 3 district hospitals, and 10 health centers in Bolikhamxay province were enrolled. Sociodemographic information was collected with a standardized questionnaire. Serum samples were analyzed for antibodies against vaccine components, and bivariate and multivariable analyses were performed to identify risk factors for low vaccine responses.ResultsSeroprotection rates at the provincial, district, and health center level were as high as in central hospitals, but seroprotection rates in areas covered by remote health centers were significantly lower. Protective levels also rapidly decreased with age at sampling. Seroprotection rates in Bolikhamxay against the different components reached 70%–77% and were up to 20% higher than in previous studies in the same region; 18.8% more children received the hepatitis B vaccine birth dose and the hepatitis B virus infection rate was 4 times lower.ConclusionsVaccine immunogenicity has dramatically improved in a central province, likely due to training and investment in the cold chain. Nevertheless, there remains a need to focus on the “last mile” in remote areas were most children are vaccinated through outreach activities.
      PubDate: Tue, 19 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz143
      Issue No: Vol. 69, No. 12 (2019)
       
  • Persistent Low-level Viremia While on Antiretroviral Therapy Is an
           Independent Risk Factor for Virologic Failure
    • Authors: Joya C; Won S, Schofield C, et al.
      Pages: 2145 - 2152
      Abstract: AbstractBackgroundWhether persistent low-level viremia (pLLV) predicts virologic failure (VF) is unclear. We used data from the US Military HIV Natural History Study (NHS), to examine the association of pLLV and VF.MethodsNHS subjects who initiated combination antiretroviral therapy (ART) after 1996 were included if they had 2 or more VLs measured with a lower limit of detection of ≤50 copies/mL. VF was defined as a confirmed VL ≥200 copies/mL or any VL >1000 copies/mL. Participants were categorized into mutually exclusive virologic categories: intermittent LLV (iLLV) (VL of 50–199 copies/mL on <25% of measurements), pLLV (VL of 50–199 copies/mL on ≥25% of measurements), high-level viremia (hLV) (VL of 200–1000 copies/mL), and continuous suppression (all VL <50 copies/mL). Cox proportional hazards models were used to evaluate the association between VF and LLV; hazard ratios and 95% confidence interval (CI) are presented.ResultsTwo thousand six subjects (median age 29.2 years, 93% male, 41% black) were included; 383 subjects (19%) experienced VF. After adjusting for demographics, VL, CD4 counts, ART regimen, prior use of mono or dual antiretrovirals, and time to ART start, pLLV (3.46 [2.42–4.93]), and hLV (2.29 [1.78–2.96]) were associated with VF. Other factors associated with VF include black ethnicity (1.33 [1.06–1.68]) and antiretroviral use prior to ART (1.79 [1.34–2.38]). Older age at ART initiation (0.71 [0.61–0.82]) and non-nucleoside reverse transcriptase inhibitor (0.68 [0.51–0.90]) or integrase strand transfer inhibitor use (0.26 [0.13–0.53]) were protective.ConclusionOur data add to the body of evidence that suggests persistent LLV is associated with deleterious virologic consequences.
      PubDate: Sat, 16 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz129
      Issue No: Vol. 69, No. 12 (2019)
       
  • Influenza Vaccine Effectiveness Against Hospitalization in Fully and
           Partially Vaccinated Children in Israel: 2015–2016, 2016–2017, and
           2017–2018
    • Authors: Segaloff H; Leventer-Roberts M, Riesel D, et al.
      Pages: 2153 - 2161
      Abstract: AbstractBackgroundInfluenza vaccine effectiveness (VE) varies by season, circulating influenza strain, age, and geographic location. There have been few studies of influenza VE among hospitalized children, particularly in Europe and the Middle East.MethodsWe estimated VE against influenza hospitalization among children aged 6 months to 8 years at Clalit Health Services hospitals in Israel in the 2015–2016, 2016–2017, and 2017–2018 influenza seasons, using the test-negative design. Estimates were computed for full and partial vaccination.ResultsWe included 326 influenza-positive case patients and 2821 influenza-negative controls (140 case patients and 971 controls from 2015–2016, 36 case patients and 1069 controls from 2016–2017, and 150 case patients and 781 controls from 2017–2018). Over all seasons, VE was 53.9% for full vaccination (95% confidence interval [CI], 38.6%–68.3%), and 25.6% for partial vaccination (−3% to 47%). In 2015–2016, most viruses were influenza A(H1N1) and vaccine lineage–mismatched influenza B/Victoria; the VE for fully vaccinated children was statistically significant for influenza A (80.7%; 95% CI, 40.3%–96.1%) but not B (23.0%; −38.5% to 59.4%). During 2016–2017, influenza A(H3N2) predominated, and VE was (70.8%; 95% CI, 17.4%–92.4%). In 2017–2018, influenza A(H3N2), H1N1 and lineage-mismatched influenza B/Yamagata cocirculated; VE was statistically significant for influenza B (63.0%; 95% CI, 24.2%–83.7%) but not influenza A (46.3%; −7.2% to 75.3%).ConclusionsInfluenza vaccine was effective in preventing hospitalizations among fully vaccinated Israeli children over 3 influenza seasons, but not among partially vaccinated children. There was cross-lineage protection in a season where the vaccine contained B/Victoria and the circulating strain was B/Yamagata, but not in a season with the opposite vaccine-circulating strain distribution.
      PubDate: Mon, 11 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz125
      Issue No: Vol. 69, No. 12 (2019)
       
  • Changes in Otitis Media Episodes and Pressure Equalization Tube Insertions
           Among Young Children Following Introduction of the 13-Valent Pneumococcal
           Conjugate Vaccine: A Birth Cohort–based Study
    • Authors: Wiese A; Huang X, Yu C, et al.
      Pages: 2162 - 2169
      Abstract: AbstractBackgroundThe impact of 13-valent pneumococcal conjugate vaccine (PCV13) introduction on the occurrence of first and subsequent otitis media (OM) episodes in early childhood is unclear. We compared the risk of OM episodes among children age <2 years before and after PCV13 introduction, accounting for the dependence between OM episodes.MethodsWe identified consecutive annual (July–June) cohorts of Tennessee Medicaid–enrolled children (2006–2014) from birth through age 2 years. We identified OM episodes using coded diagnoses (we classified diagnoses <21 days apart as the same episode). We modeled adjusted hazard ratios (aHRs) for OM comparing 7-valent pneumococcal conjugate vaccine (PCV7)–era (2006–2010) and PCV13-era (2011–2014) birth cohorts, accounting for risk factors and dependence between first and subsequent episodes. Secondary analyses examined pressure equalization tube (PET) insertions and compared the risk of recurrent OM (≥3 episodes in 6 months or ≥4 episodes in 12 months) between PCV7- and PCV13-era birth cohorts.ResultsWe observed 618 968 OM episodes and 24 875 PET insertions among 368 063 children. OM and PET insertion rates increased during the PCV7 years and declined after PCV13 introduction. OM and PET insertion risks were lower in the 2013–2014 cohort compared with the 2009–2010 cohort (aHRs [95% confidence interval], 0.92 [.91–.93] and 0.76 [.72–.80], respectively). PCV13 introduction was associated with declines in the risk of first, subsequent, and recurrent OM.ConclusionsThe transition from PCV7 to PCV13 was associated with a decline of OM among children aged <2 years due to a reduction in the risk of both the first and subsequent OM episodes.
      PubDate: Sat, 16 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz142
      Issue No: Vol. 69, No. 12 (2019)
       
  • Trichomonas vaginalis Virus Among Women With Trichomoniasis and
           Associations With Demographics, Clinical Outcomes, and Metronidazole
           Resistance
    • Authors: Graves K; Ghosh A, Schmidt N, et al.
      Pages: 2170 - 2176
      Abstract: AbstractBackgroundTrichomonas vaginalis virus (TVV) is a non-segmented, 4.5–5.5 kilo-base pair (kbp), double-stranded RNA virus infecting T. vaginalis. The objectives of this study were to examine the TVV prevalence in US Trichomonas vaginalis isolates and TVV’s associations with patient demographics, clinical outcomes, and metronidazole resistance.MethodsArchived T. vaginalis isolates from the enrollment visits of 355 women participating in a T. vaginalis treatment trial in Birmingham, Alabama, were thawed and grown in culture. Their total RNA was extracted using a Trizol reagent. Contaminating, single-stranded RNA was precipitated using 4.0 M Lithium Chloride and centrifugation. The samples were analyzed by gel electrophoresis to visualize a 4.5 kbp band representative of TVV. In vitro testing for metronidazole resistance was also performed on 25/47 isolates obtained from the women’s test of cure visits.ResultsTVV was detected in 142/355 (40%) isolates at the enrollment visit. Women with TVV-positive (TVV+) isolates were significantly older (P = .01), more likely to smoke (P = .04), and less likely to report a history of gonorrhea (P = .04). There was no association between the presence of clinical symptoms or repeat T. vaginalis infections with TVV+ isolates (P = .14 and P = .44, respectively). Of 25 test of cure isolates tested for metronidazole resistance, 0/10 TVV+ isolates demonstrated resistance, while 2/15 TVV-negative isolates demonstrated mild to moderate resistance (P = .23).ConclusionsOf 355 T. vaginalis isolates tested for TVV, T. vaginalis isolates tested for TVV, the prevalence was 40%. However, there was no association of TVV+ isolates with clinical symptoms, repeat infections, or metronidazole resistance. These results suggest that TVV may be commensal to T. vaginalis.
      PubDate: Fri, 15 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz146
      Issue No: Vol. 69, No. 12 (2019)
       
  • Indirect Effects of 10-Valent Pneumococcal Conjugate Vaccine Against Adult
           Pneumococcal Pneumonia in Rural Western Kenya
    • Authors: Bigogo G; Audi A, Auko J, et al.
      Pages: 2177 - 2184
      Abstract: AbstractBackgroundData on pneumococcal conjugate vaccine (PCV) indirect effects in low-income countries with high human immunodeficiency virus (HIV) burden are limited. We examined adult pneumococcal pneumonia incidence before and after PCV introduction in Kenya in 2011.MethodsFrom 1 January 2008 to 31 December 2016, we conducted surveillance for acute respiratory infection (ARI) among ~12 000 adults (≥18 years) in western Kenya, where HIV prevalence is ~17%. ARI cases (cough or difficulty breathing or chest pain, plus temperature ≥38.0°C or oxygen saturation <90%) presenting to a clinic underwent blood culture and pneumococcal urine antigen testing (UAT). We calculated ARI incidence and adjusted for healthcare seeking. The proportion of ARI cases with pneumococcus detected among those with complete testing (blood culture and UAT) was multiplied by adjusted ARI incidence to estimate pneumococcal pneumonia incidence.ResultsPre-PCV (2008–2010) crude and adjusted ARI incidences were 3.14 and 5.30/100 person-years-observation (pyo), respectively. Among ARI cases, 39.0% (340/872) had both blood culture and UAT; 21.2% (72/340) had pneumococcus detected, yielding a baseline pneumococcal pneumonia incidence of 1.12/100 pyo (95% confidence interval [CI]: 1.0–1.3). In each post-PCV year (2012–2016), the incidence was significantly lower than baseline; with incidence rate ratios (IRRs) of 0.53 (95% CI: 0.31–0.61) in 2012 and 0.13 (95% CI: 0.09–0.17) in 2016. Similar declines were observed in HIV-infected (IRR: 0.13; 95% CI: 0.08–0.22) and HIV-uninfected (IRR: 0.10; 95% CI: 0.05–0.20) adults.ConclusionsAdult pneumococcal pneumonia declined in western Kenya following PCV introduction, likely reflecting vaccine indirect effects. Evidence of herd protection is critical for guiding PCV policy decisions in resource-constrained areas.
      PubDate: Sat, 16 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz139
      Issue No: Vol. 69, No. 12 (2019)
       
  • High-risk Human Papilloma Virus Testing Improves Diagnostic Performance to
           Predict Moderate- to High-grade Anal Intraepithelial Neoplasia in Human
           Immunodeficiency Virus–infected Men Who Have Sex With Men in
           Low-to-Absent Cytological Abnormalities
    • Authors: Viciana P; , Milanés-Guisado Y, et al.
      Pages: 2185 - 2192
      Abstract: AbstractBackgroundScreening methods for anal squamous intraepithelial lesions (SILs) are suboptimal. We aimed to determine the diagnostic performance of a composite endpoint comprising anal liquid-based cytology (aLBC) and high-risk human papillomavirus (HR-HPV) testing to predict histological high-grade SILs (hHSILs).MethodsFrom the SeVIHanal cohort, human immunodeficiency virus (HIV)–infected men who have sex with men (MSM) who had an aLBC with concomitant HR-HPV testing were included. hHSILs were determined by high-resolution anoscopy (HRA)–guided biopsy.ResultsA total of 705 visits obtained from 426 patients were included. The prevalence of HR-HPV among aLBC results were 51.9% (133/215) normal, 87.9% (20/232) low-grade SILs (LSILs), and 90.9% (149/164) high-grade SILs; P (linear association) < .001. Low prevalence of hHSILs was only observed for the composite aLBC/HR-HPV testing endpoint “normal/noHR-HPV” (10%) and “LSIL/noHR-HPV” (4%). The prognostic values (95% confidence interval) for HR-HPV to predict hHSILs in normal cytology were positive predictive value (PPV), 29.3% (25.6%–33.3%); negative predictive value (NPV), 90.2% (82.8%–94.7%); sensitivity, 83% (69.2%–92.4%); and specificity, 44.1% (36.4%–51.9%). Corresponding figures for cytologic LSILs were PPV, 39.2% (37.4%–41.1%); NPV, 96.4% (78.9%–99.5%); sensitivity, 98.8% (93.3%–99.9%); and specificity, 17.9% (12.1%–24.9%). A positive interaction and a synergistic effect for the composite endpoint were observed (relative excess risk = 1.50, attributable proportion of histological results to interaction = 0.17, synergy index = 1.24).ConclusionsHRA should not be indicated in the setting of LSILs/noHR-HPV following aLBC-based screening. In contrast, HIV-infected MSM with normal aLBC/HR-HPV infection should be considered for HRA.Clinical Trials RegistrationNCT03713229.
      PubDate: Sat, 16 Feb 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz144
      Issue No: Vol. 69, No. 12 (2019)
       
  • 48-Year-Old Male With Febrile Neutropenia and Massive Hemolysis
    • Authors: Jakharia N; Hossain A, Luethy P, et al.
      Pages: 2193 - 2194
      Abstract: A 48-year-old male previously diagnosed with high-risk acute myeloid leukemia presented to the emergency department with 2 days of progressive lethargy and fever. He received daunorubicin and cytarabine induction attaining complete remission and had completed cycle 4 of consolidation with cytarabine 2 weeks prior to presentation. His absolute neutrophil count was less than 500 for 2 weeks prior to presentation, and he was taking levofloxacin prophylaxis. A complete blood count from 3 days prior to admission had a white blood cell count of 0.1 K/mcL, Hb of 9.1 g/dL, and platelets of 26 K/mcL. On presentation he was obtunded, febrile to 103.2° F, BP 79/42 mm of Hg, and pulse of 144/min. The remainder of his exam was unremarkable. He was treated empirically with vancomycin, meropenem, and micafungin. Laboratory values at presentation were significant for lactic acid of 15 mmol/L, total bilirubin 13.6 mg/dL, creatinine 4.83 mg/dL, and LDH 17 000 units/L. Multiple samples of his blood were hemolysed, and a complete blood count could not be obtained (Figure 1). The peripheral blood smear is shown (Figure 2), prompting an urgent consultation to infectious disease. The patient died within 18 hours from presentation despite maximal life support.
      PubDate: Wed, 27 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz042
      Issue No: Vol. 69, No. 12 (2019)
       
  • Ending the Epidemic in America Will Not Happen if the Status Quo
           Continues: Modeled Projections for Human Immunodeficiency Virus Incidence
           in 6 US Cities
    • Authors: Nosyk B; , Zang X, et al.
      Pages: 2195 - 2198
      Abstract: AbstractWe estimated 10-year (2020–2030) trajectories for human immunodeficiency virus incidence in 6 US cities. Estimated incidence will only decrease in 2 of 6 cities, with the overall population-weighted incidence decreasing 3.1% (95% credible interval [CrI], ˗1.0% to 8.5%) by 2025, and 4.3% (95% CrI, ˗2.6% to 12.7%) by 2030 across cities. Targeted, context-specific combination implementation strategies will be necessary to meet the newly established national targets.
      PubDate: Mon, 14 Oct 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1015
      Issue No: Vol. 69, No. 12 (2019)
       
  • Ending the Human Immunodeficiency Virus Epidemic: Towards an
           Evidence-Based Approach
    • Authors: Fojo A; Dowdy D.
      Pages: 2199 - 2200
      Abstract: HIV“ending the HIV epidemic” planepidemics/prevention & controldynamic transmission model
      PubDate: Mon, 14 Oct 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1018
      Issue No: Vol. 69, No. 12 (2019)
       
  • Decreased Tenofovir Diphosphate Concentrations in a Transgender Female
           Cohort: Implications for Human Immunodeficiency Virus Preexposure
           Prophylaxis
    • Authors: Cottrell M; Prince H, Schauer A, et al.
      Pages: 2201 - 2204
      Abstract: AbstractFeminizing hormone therapy (FHT) may interact with human immunodeficiency virus preexposure prophylaxis (PrEP). We found that transgender women who took FHT exhibited a 7-fold lower rectal tissue ratio of PrEP’s active metabolites vs competing deoxynucleotides compared to cisgender women and men (P = .03) that inversely correlated with estradiol (ρ = –0.79; P < .05). Thus, FHT may negatively impact PrEP efficacy.Clinical Trials Registration. NCT02983110.
      PubDate: Tue, 09 Apr 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz290
      Issue No: Vol. 69, No. 12 (2019)
       
  • Preemptive Tecovirimat Use in an Active Duty Service Member Who Presented
           With Acute Myeloid Leukemia After Smallpox Vaccination
    • Authors: Lindholm D; Fisher R, Montgomery J, et al.
      Pages: 2205 - 2207
      Abstract: AbstractSmallpox vaccine is contraindicated in immunosuppression due to increased risk for adverse reactions (eg, progressive vaccinia). We describe the first-ever use of tecovirimat as a preemptive vaccinia virus treatment strategy during induction chemotherapy in an active duty service member who presented with acute leukemia and inadvertent autoinoculation after smallpox vaccination.
      PubDate: Tue, 09 Apr 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz286
      Issue No: Vol. 69, No. 12 (2019)
       
  • The Impact of Human Immunodeficiency Virus Exposure on Respiratory
           Syncytial Virus–associated Severe Respiratory Illness in South African
           Infants, 2011–2016
    • Authors: McMorrow M; Tempia S, Walaza S, et al.
      Pages: 2208 - 2211
      Abstract: AbstractFrom 2011 through 2016, we conducted surveillance for severe respiratory illness in infants. Human immunodeficiency virus exposure significantly increased the risk of respiratory syncytial virus (RSV)–associated hospitalization in infants aged <5 months. More than 60% of RSV-associated hospitalizations occurred in the first 4 months of life and may be preventable through maternal vaccination or birth-dose monoclonal antibody.
      PubDate: Tue, 09 Apr 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz288
      Issue No: Vol. 69, No. 12 (2019)
       
  • Ending the Human Immunodeficiency Virus Pandemic: Optimizing the
           Prevention and Treatment Toolkits
    • Authors: Eisinger R; Folkers G, Fauci A.
      Pages: 2212 - 2217
      Abstract: AbstractUnprecedented basic and clinical biomedical research advances over the past 4 decades have led to the development of “toolkits” of highly effective interventions for preventing and treating human immunodeficiency virus (HIV). Despite many successes in decreasing the incidence and mortality of HIV, major challenges remain in the goal of ending the HIV pandemic in the United States and globally. Overcoming these challenges will require optimization of the implementation of existing interventions for HIV prevention and treatment together with the continued development of new and innovative approaches that can be readily utilized by individuals with HIV and those at risk of infection.
      PubDate: Thu, 24 Oct 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz998
      Issue No: Vol. 69, No. 12 (2019)
       
  • The Consensus Hepatitis C Cascade of Care: Standardized Reporting to
           Monitor Progress Toward Elimination
    • Authors: Safreed-Harmon K; Blach S, Aleman S, et al.
      Pages: 2218 - 2227
      Abstract: AbstractCascade-of-care (CoC) monitoring is an important component of the response to the global hepatitis C virus (HCV) epidemic. CoC metrics can be used to communicate, in simple terms, the extent to which national and subnational governments are advancing on key targets, and CoC findings can inform strategic decision-making regarding how to maximize the progression of individuals with HCV to diagnosis, treatment, and cure. The value of reporting would be enhanced if a standardized approach were used for generating CoCs. We have described the Consensus HCV CoC that we developed to address this need and have presented findings from Denmark, Norway, and Sweden, where it was piloted. We encourage the uptake of the Consensus HCV CoC as a global instrument for facilitating clear and consistent reporting via the World Health Organization (WHO) viral hepatitis monitoring platform and for ensuring accurate monitoring of progress toward WHO's 2030 hepatitis C elimination targets.
      PubDate: Sun, 28 Jul 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz714
      Issue No: Vol. 69, No. 12 (2019)
       
  • Immunonutrition in Human Immunodeficiency Virus Infection: Which
           Populations to Target'
    • Authors: Taramasso L; Bozzi G, Muscatello A, et al.
      Pages: 2228 - 2229
      Abstract: To the Editor—We read with great interest the recent article published by Serrano-Villar et al regarding immunonutrition supplementation in patients living with human immunodeficiency virus (HIV) with advanced stage of immunodeficiency [1]. This randomized placebo-controlled trial addressed a very important research question: Might a combined prebiotic and probiotic approach, by reducing immune activation, enhance immune recovery in HIV patients starting antiretroviral therapy (ART) at advanced stages of immune depletion' To answer this question, 78 patients were randomized and 59 completed the follow-up at week 48. Median CD4+ T-cell count was 225 cells/μL (interquartile range [IQR], 117–228) and the CD4/CD8 ratio was 0.27 (IQR, 0.13–0.34). The effects of the immunonutrition approach on immune recovery and inflammation were not statistically different compared to those observed in the placebo arm; of note, high rate of discontinuation and poor adherence to the intervention were reported. However, such results do not seem surprising considering the profound effects that untreated HIV infection exerts on gut structure and function. Even though mucosal CD4 T-cell depletion occurs early in HIV infection, microbial translocation is chronic in HIV [2], and late-treated individuals have impaired gut junctional complexes and extensive colonic epithelial barrier damage, after long-term exposure to bacterial products and chronic inflammation [3]. In contrast, people with earlier HIV infection could actually benefit from a targeted immunonutrition effect. Previous studies have linked probiotic administration to significant CD4+ T-cell recovery in patients with mean CD4 count >350 cells/μL [4] and to reduction of CD4+CD38+HLA-DR+ and CD8+CD38+HLA-DR+ T cells, increase in T-helper 17 cell subsets, and gut epithelial barrier recovery in patients with median CD4 count >500 cells/μL [5]. Furthermore, prebiotic use has been demonstrated to promote significant reduction in immune activation markers in patients with high CD4+ T cells. For example, administration of an oligosaccharide mixture promoted significant reduction in blood levels of soluble CD14 and CD4+CD25+ T cells in naive individuals with mean CD4+ T cells >500 cells/μL, and increased natural killer cell activity compared to placebo [6]. In another study conducted by Serrano-Villar et al, prebiotic intervention was shown to be associated with significant decrease of activated CD4+HLA-DR+CD38+ cells in patients with median CD4+ T cells >500 cells/μL (both untreated patients and immunological ART responders), whereas such an association was not confirmed in immunological nonresponders with lower CD4 counts (median <300 CD4+ T cells/μL) [7].
      PubDate: Fri, 26 Apr 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz337
      Issue No: Vol. 69, No. 12 (2019)
       
  • Reply to Taramasso et al
    • Authors: Serrano-Villar S; Estrada V.
      Pages: 2229 - 2229
      Abstract: To the Editor—We thank Taramasso et al [1] for their thoughtful letter regarding the results of the PROMALTIA study [2]. The authors pointed out that our negative findings disagree with previous works in human immunodeficiency virus (HIV)-infected individuals, which indicated beneficial immunologic effects of different nutritional immunomodulatory interventions [3–6]. Possible explanations for this discrepancy include the high heterogeneity in the type and duration of the nutritional interventions assessed and differences in the immunovirological profile of the study participants, but also methodologic issues, such as exploratory designs without predefined primary outcomes or sample size calculations, and measurement of a high number of biomarkers. These factors could also explain the lack of consistency in the outcomes reported as statistically significant across the previous studies [6]. Admittedly, we cannot rule out that a different nutritional intervention would have yielded a different outcome.
      PubDate: Sat, 06 Apr 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz341
      Issue No: Vol. 69, No. 12 (2019)
       
  • Evidence in a Cluster Randomized Controlled Trial of Increased 2009
           Pandemic Risk Associated With 2008–2009 Seasonal Influenza Vaccine
           Receipt
    • Authors: Skowronski D; De Serres G.
      Pages: 2230 - 2231
      Abstract: To the Editor—The 2009 influenza A(H1N1) pandemic provided a unique opportunity to evaluate seasonal influenza vaccine effects on pandemic risk. When A(H1N1)pdm09 viruses arose in April 2009, the Canadian Sentinel Practitioner Surveillance Network (SPSN) was already well established for annual influenza vaccine effectiveness (VE) monitoring using the test-negative design (TND) [1, 2]. Without pause or protocol change, the SPSN extended its ongoing evaluation of the 2008/2009 trivalent inactivated influenza vaccine (2008/09-IIV3) to also capture effects on A(H1N1)pdm09 risk during the first 2009 spring–summer pandemic wave [2].
      PubDate: Mon, 06 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz351
      Issue No: Vol. 69, No. 12 (2019)
       
  • Reply to Skowronski and De Serres
    • Authors: Ortiz J; Sugimoto J, Neuzil K, et al.
      Pages: 2231 - 2232
      Abstract: To the Editor—Skowronski and De Serres summarized evidence of increased attack rates with 2009 pandemic influenza A virus (A/H1N1pdm09) following receipt of 2008–2009 Northern Hemisphere trivalent inactivated influenza vaccine (IIV3) [1]. They postulated that exposure to previously circulating influenza A viruses may have modified the immune response to the IIV3 in a way that led to decreased or negative vaccine effectiveness (VE) against illness caused by A/H1N1pdm09. To further explore this hypothesis, they proposed that we collapse age groupings in analyses of total vaccine effectiveness from our trial in Senegal [2] to dichotomize children as having all had prior exposure to influenza A viruses or not. Skowronski and De Serres suggested age groupings based on a study from the Netherlands in which 100% of children had serologic evidence of prior infection with a previously circulating influenza A virus by the age of 6 years, as determined by hemagglutination inhibition (HI) assay [3].
      PubDate: Mon, 06 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz352
      Issue No: Vol. 69, No. 12 (2019)
       
  • Letter to the Editor
    • Authors: Khoruts A; Sadowsky M.
      Pages: 2232 - 2233
      Abstract: To the Editor—We read with curiosity the systematic review and meta-analysis by Tariq and colleagues [1] that claimed in its title that fecal microbiota transplantation (FMT) led to low cure rates of Clostridium difficile infections in controlled trials. The title is important, as it may be the only part of the article seen by many clinicians and may be amplified in the media. Therefore, we feel there are several points concerning this publication that need to be emphasized.
      PubDate: Sat, 04 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz366
      Issue No: Vol. 69, No. 12 (2019)
       
  • Reply to Khoruts and Sadowsky
    • Authors: Khanna S; Tariq R, Pardi D.
      Pages: 2233 - 2234
      Abstract: To the Editor—We appreciate the interest of Drs Khoruts and Sadowsky in our recently published study in which we evaluated the efficacy of fecal microbiota transplantation (FMT) in controlled trials [1, 2]. We completely agree that FMT is an efficacious treatment option in patients with recurrent Clostridium difficile infection, most of whom have failed multiple antibiotic treatments. The main point of our meta-analysis is that there is a discrepancy in the success rates reported in clinical trials of FMT compared to rates from observational studies.
      PubDate: Fri, 03 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz367
      Issue No: Vol. 69, No. 12 (2019)
       
  • Is Oral Ribavirin for the Treatment of Respiratory Syncytial Virus in
           High-risk Hematopoietic Stem Cell Transplant Recipients Really Safe'
    • Authors: Jain S; Phoompoung P, Husain S.
      Pages: 2234 - 2235
      Abstract: ribavirintransplantrespiratory syncytial virus
      PubDate: Fri, 10 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz376
      Issue No: Vol. 69, No. 12 (2019)
       
  • Reply to Jain et al
    • Authors: Foolad F; Chemaly R.
      Pages: 2235 - 2236
      Abstract: To the Editor—We thank Jain et al for their thoughtful comments on our study comparing the outcomes of treatment with oral vs aerosolized ribavirin (RBV) in hematopoietic cell transplant (HCT) recipients with respiratory syncytial virus (RSV) infections [1]. With the significant increase in the cost of aerosolized RBV ($30 000 per day), a randomized controlled trial of oral vs aerosolized RBV for the treatment of RSV in HCT recipients is unlikely to be undertaken [2]. Owing to financial restrictions, many institutions, including ours, adopted oral RBV as an alternative therapy for RSV infection in HCT recipients. With all of the limitations of any retrospective study in mind, we aimed to identify any signal of worse outcomes after the switch of formulations occurred in our center [1].
      PubDate: Fri, 10 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz379
      Issue No: Vol. 69, No. 12 (2019)
       
  • Genetic Evidence That Naive T Cells Can Contribute Significantly to the
           Human Immunodeficiency Virus Intact Reservoir: Time to Re-evaluate Their
           Role
    • Authors: Venanzi Rullo E; Cannon L, Pinzone M, et al.
      Pages: 2236 - 2237
      Abstract: HIVnaivememoryreservoir
      PubDate: Tue, 07 May 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz378
      Issue No: Vol. 69, No. 12 (2019)
       
  • Erratum
    • Pages: 2238 - 2238
      Abstract: An error appeared in the corrected proof publication of this article [Silva MMO, Tauro, LB, Kikuti M, et al. Concomitant Transmission of Dengue, Chikungunya, and Zika Viruses in Brazil: Clinical and Epidemiological Findings From Surveillance for Acute Febrile Illness. Clin Infect Dis: https://doi.org/10.1093/cid/ciy1083].
      PubDate: Fri, 01 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz588
      Issue No: Vol. 69, No. 12 (2019)
       
  • Erratum
    • Pages: 2238 - 2238
      Abstract: An error appeared in the corrected proof publication of this article [Zhao X-Y, Pei X-Y, Chang Y-J, et al. Effects of First-line Therapy With Donor-derived Human Cytomegalovirus (HCMV)–specific T Cells Reduces Persistent HCMV Infection by Promoting Antiviral Immunity After Allogenic Stem Cell Transplantation. Clin Infect Dis https://doi.org/10.1093/cid/ciz368]. This article was originally published with the following affiliation error:
      PubDate: Fri, 01 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1021
      Issue No: Vol. 69, No. 12 (2019)
       
  • Erratum
    • Authors: Al-Hasan M; Baddour L.
      Pages: 2238 - 2238
      Abstract: The following error appeared in the corrected proof publication of this article [Al-Hasan MN and Baddour LM Resilience of the Pitt Bacteremia Score: 3 Decades and Counting. Clin Infect Dis https://doi.org/10.1093/cid/ciz535].
      PubDate: Tue, 22 Oct 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1041
      Issue No: Vol. 69, No. 12 (2019)
       
  • Erratum
    • Pages: 2239 - 2239
      Abstract: The following error appeared in the corrected proof publication of this article [Han Y, Yin Y, Dai X, et al. Widespread Use of High-dose Ceftriaxone Therapy for Uncomplicated Gonorrhea Without Reported Ceftriaxone Treatment Failure: Results From 5 Years of Multicenter Surveillance Data in China. Clin Infect Dis https://doi.org/10.1093/cid/ciz170].
      PubDate: Tue, 26 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1066
      Issue No: Vol. 69, No. 12 (2019)
       
  • Erratum
    • Pages: 2239 - 2239
      Abstract: The following errors appeared in the corrected proof publication of this article [Levin MJ and Weinberg A. Adjuvanted Recombinant Glycoprotein E Herpes Zoster Vaccine. Clin Infect Dis https://doi.org/10.1093/cid/ciz770].
      PubDate: Mon, 04 Nov 2019 00:00:00 GMT
      DOI: 10.1093/cid/ciz1056
      Issue No: Vol. 69, No. 12 (2019)
       
 
 
JournalTOCs
School of Mathematical and Computer Sciences
Heriot-Watt University
Edinburgh, EH14 4AS, UK
Email: journaltocs@hw.ac.uk
Tel: +00 44 (0)131 4513762
Fax: +00 44 (0)131 4513327
 
Home (Search)
Subjects A-Z
Publishers A-Z
Customise
APIs
Your IP address: 3.94.129.211
 
About JournalTOCs
API
Help
News (blog, publications)
JournalTOCs on Twitter   JournalTOCs on Facebook

JournalTOCs © 2009-